Behandeling van gevorderd prostaatcarcinoom met een depotvorm van LH-RH-analogon: eerste endocrinologische en klinische resultaten

– Fifty-five patients with advanced prostatic carcinoma were treated with a new depot preparation of an LH-RH-analogue. Monthly repeated subcutaneous injections of the depot caused no significant local or systemic adverse reactions. Clinical results were comparable with those obtained by hormonal or surgical therapy, however without their disadvantages except those induced by testosterone depletion. Objective response rates after 6 months were up to 69. The authors feel that this therapy promises to be a valuable extension of the therapeutic arsenal in prostatic carcinoma.